New Zealand, U.S. Researchers Develop Better Drug For Resistant TB
This article was originally published in PharmAsia News
Executive Summary
New Zealand scientists working with U.S. colleagues are enthusiastic about a new compound dubbed TBA-354, which they say is proving more effective than PA-824, to date considered the most-effective treatment for drug-resistant tuberculosis.
New Zealand scientists working with U.S. colleagues are enthusiastic about a new compound dubbed TBA-354, which they say is proving more effective than PA-824, to date considered the most-effective treatment for drug-resistant tuberculosis. PA-824 has passed early clinical trials for use in combination with the TB drug normally used for treating resistant TB, but TBA-354 is showing in preclinical studies it could be effective after four months of treatment, versus up to two years for the other. The researchers hope to begin clinical trials in the U.S. next year. (Click here for more
)
"New Tuberculosis Drug Being Developed" - New Zealand Herald (9/18/2012)